{'fraction_non_alphanumeric': 0.03582853486884197, 'fraction_numerical': 0.02815099168266155, 'mean_word_length': 5.436213991769547, 'pattern_counts': {'":': 0, '<': 3, '<?xml version=': 0, '>': 2, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A prospective randomized trial comparing repeated endoscopic sclerotherapy and propranolol in decompensated (child class B and C) cirrhotic patients

A prospective randomized study was conducted to compare the efficacy of long‐term endoscopic sclerotherapy vs. propranolol in Child class B and C patients with variceal bleeds within the 30 days before the study. Forty‐five and 46 patients were randomized to receive sclerotherapy and propranolol, respectively, after preentry stratification for Child scores. Sclerotherapy was administered with 1% polidocanol at 10‐day intervals until obliteration of varices was achieved. Propranolol was administered to achieve a reduction in resting pulse rate of 25%. Rebleeding occurred in 19 patients undergoing sclerotherapy and in 31 receiving propranolol (p < 0.05). The number of episodes of rebleeding was higher (p < 0.05) in the propranolol group (n = 64) than in the sclerotherapy group (n = 35). The mean bleeding risk factor, number of hospitalizations for rebleeding and blood transfusion requirement were also significantly higher in the propranolol‐treated patients. The median bleed‐free period was more than 36 mo in the sclerotherapy group and 2.5 mo in the propranolol group (p < 0.01). The median survival time was significantly longer in the sclerotherapy group (>36 mo) than in the propranolol group (>24 mo). We conclude that in decompensated cirrhotic patients, long‐term endoscopic sclerotherapy is superior to propranolol in preventing rebleeding and improving survival. (HEPATOLOGY 1992;16:89–94.)